Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

Icotinib could have potential effect and tolerability when used sequentially with chemotherapy for advanced epidermal growth factor receptor (To evaluate the efficacy and safety of chemotherapy followed by icotinib maintenance therapy as first-line treatment for advancedThis multicenter, open-label, pilot randomized controlled trial enrolled 68The median progression-free survival in the icotinib alone and chemotherapy + icotinib groups was 8.0 mo (95%CI: 3.84-11.63) and 13.4 mo (95%CI: 10.18-16.33), respectively (A sequential combination of chemotherapy and EGFR-tyrosine kinase inhibitor is feasible for stage IV